Bio-Rad and Bruker Sign Joint Product Development and Co-Marketing Agreement
24 March 2009 - 7:30AM
Marketwired
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIOb), a
multinational manufacturer and distributor of life science research
and clinical diagnostic products, and Bruker Corporation (NASDAQ:
BRKR), a leading manufacturer of mass spectrometry (MS)
instruments, today announced that they have signed an exclusive
partnership agreement to develop and market new products based on
Bio-Rad's surface-enhanced laser desorption/ionization (SELDI)
technology in combination with Bruker's matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF/TOF) mass
spectrometers for applications of high-throughput protein profiling
and identification. The products will provide new solutions for
biomarker discovery, in particular, the detection and
high-confidence identification of intact peptides and proteins
under 30 kilodaltons, which are known to be challenging for
currently available technologies to identify.
"We're confident that Bio-Rad's SELDI technology combined with
the flexibility delivered by Bruker's TOF/TOF systems will offer
tangible benefits to researchers for protein biomarker discovery,"
said Brad Crutchfield, Bio-Rad Vice President and Life Science
Group Manager. "We welcome the opportunity to work with Bruker, a
company that, similar to Bio-Rad, has a long history of advancing
life science research through its commitment to customer
support."
"We are excited about working with Bio-Rad," said Dr. Gary
Kruppa, Vice President for Business Development at Bruker
Daltonics. "Bruker Daltonics' high-performance TOF/TOF technology
will bring a new dimension to protein profiling and identification,
expanding the capabilities of Bio-Rad's established SELDI
technology. New products based on this combination of technologies
will allow access to new technical capabilities and new market
segments in applied proteomics, enabling researchers to better
identify and characterize new biomarkers."
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIOb), has
remained at the center of scientific discovery for more than 50
years, manufacturing and distributing a broad range of products for
the life science research and clinical diagnostic markets. Bio-Rad
is renowned worldwide among hospitals, universities, major research
institutions, as well as biotechnology and pharmaceutical companies
for its commitment to quality and customer service. Founded in
1952, Bio-Rad is headquartered in Hercules, California, and serves
more than 85,000 research and industry customers worldwide through
its global network of operations. The company employs over 6,500
people globally and had revenues exceeding $1.7 billion in 2008.
For more information, visit www.bio-rad.com.
About Bruker Daltonics
Bruker Daltonics is a leading manufacturer of mass spectrometry
(MS) instruments and accessories for life science, pharmaceutical,
biochemical and chemical research as well as for applied analytical
tasks in forensics and food safety. Technical solutions are based
on a comprehensive range of MALDI-TOF/TOF, ESI-Qq-TOF, ESI-ITMS,
and ESI/MALDI-FTMS mass spectrometry systems, as well as automated
sample handling systems and productivity enhancing software. For
more information about Bruker Daltonics and Bruker Corporation
(NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.
This release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as, "believe," "expect," "may,"
"will," "intend," "estimate," "continue," or similar expressions or
the negative of those terms or expressions. Such statements involve
risks and uncertainties, which could cause actual results to vary
materially from those expressed in or indicated by the
forward-looking statements. For further information regarding the
Company's risks and uncertainties, please refer to the "Risk
Factors" in the Company's public reports filed with the Securities
and Exchange Commission, including the Company's most recent Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. The Company cautions you not to place undue
reliance on forward-looking statements, which reflect an analysis
only and speak only as of the date hereof. Bio-Rad Laboratories,
Inc., disclaims any obligation to update these forward-looking
statements.
For more information, contact: Bio-Rad Laboratories, Inc. Tina
Cuccia Corporate Communications Manager 510-724-7000 Email Contact
Bruker Corporation Stacey Desrochers Investor Relations
978-663-3660 x 1115 Email Contact
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024